(Q36237720)

12 August 2017

1 reference

title

Current treatment strategies for pulmonary arterial hypertension (English)

1 reference

12 August 2017

1 reference

Lee SH

1

1 reference

12 August 2017

Rubin LJ

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Journal of Internal Medicine

12 August 2017

published in

1 reference

12 August 2017

volume

258

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

199-215

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Inflammation and obstructive sleep apnea syndrome: how many ways do I look at thee?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Nocturnal periodic breathing in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Prostacyclin and its analogues in the treatment of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Gene transfer of the Na+,K+-ATPase beta1 subunit using electroporation increases lung liquid clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Prostanoid therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Pharmacological characterization of Ca2+ entry channels in endothelin-1-induced contraction of rat aorta using LOE 908 and SK&F 96365

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Activation of three types of voltage-independent Ca2+ channel in A7r5 cells by endothelin-1 as revealed by a novel Ca2+ channel blocker LOE 908.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant report--2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

Combination therapy for pulmonary arterial hypertension: still more questions than answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01542.X

10.1111/J.1365-2796.2005.01542.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference